Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?
The search for molecules to be targeted that are involved in apoptosis resistance/increased survival and pathogenesis of onco-hematological malignancies is ongoing since these diseases are still not completely understood. Over the years, a good candidate has been identified in the Heat Shock Protein...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/4/604 |
| _version_ | 1797606243770040320 |
|---|---|
| author | Nayla Mouawad Guido Capasso Edoardo Ruggeri Leonardo Martinello Filippo Severin Andrea Visentin Monica Facco Livio Trentin Federica Frezzato |
| author_facet | Nayla Mouawad Guido Capasso Edoardo Ruggeri Leonardo Martinello Filippo Severin Andrea Visentin Monica Facco Livio Trentin Federica Frezzato |
| author_sort | Nayla Mouawad |
| collection | DOAJ |
| description | The search for molecules to be targeted that are involved in apoptosis resistance/increased survival and pathogenesis of onco-hematological malignancies is ongoing since these diseases are still not completely understood. Over the years, a good candidate has been identified in the Heat Shock Protein of 70kDa (HSP70), a molecule defined as “the most cytoprotective protein ever been described”. HSP70 is induced in response to a wide variety of physiological and environmental insults, allowing cells to survive lethal conditions. This molecular chaperone has been detected and studied in almost all the onco-hematological diseases and is also correlated to poor prognosis and resistance to therapy. In this review, we give an overview of the discoveries that have led us to consider HSP70 as a therapeutic target for mono- or combination-therapies in acute and chronic leukemias, multiple myeloma and different types of lymphomas. In this <i>excursus</i>, we will also consider HSP70 partners, such as its transcription factor HSF1 or its co-chaperones whose druggability could indirectly affect HSP70. Finally, we will try to answer the question asked in the title of this review considering that, despite the effort made by research in this field, HSP70 inhibitors never reached the clinic. |
| first_indexed | 2024-03-11T05:12:26Z |
| format | Article |
| id | doaj.art-d2a2abb04cf74cd7998312e200d02a88 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-11T05:12:26Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-d2a2abb04cf74cd7998312e200d02a882023-11-17T18:28:48ZengMDPI AGBiomolecules2218-273X2023-03-0113460410.3390/biom13040604Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?Nayla Mouawad0Guido Capasso1Edoardo Ruggeri2Leonardo Martinello3Filippo Severin4Andrea Visentin5Monica Facco6Livio Trentin7Federica Frezzato8Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, ItalyHematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, ItalyHematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, ItalyHematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, ItalyHematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, ItalyHematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, ItalyHematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, ItalyHematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, ItalyHematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, ItalyThe search for molecules to be targeted that are involved in apoptosis resistance/increased survival and pathogenesis of onco-hematological malignancies is ongoing since these diseases are still not completely understood. Over the years, a good candidate has been identified in the Heat Shock Protein of 70kDa (HSP70), a molecule defined as “the most cytoprotective protein ever been described”. HSP70 is induced in response to a wide variety of physiological and environmental insults, allowing cells to survive lethal conditions. This molecular chaperone has been detected and studied in almost all the onco-hematological diseases and is also correlated to poor prognosis and resistance to therapy. In this review, we give an overview of the discoveries that have led us to consider HSP70 as a therapeutic target for mono- or combination-therapies in acute and chronic leukemias, multiple myeloma and different types of lymphomas. In this <i>excursus</i>, we will also consider HSP70 partners, such as its transcription factor HSF1 or its co-chaperones whose druggability could indirectly affect HSP70. Finally, we will try to answer the question asked in the title of this review considering that, despite the effort made by research in this field, HSP70 inhibitors never reached the clinic.https://www.mdpi.com/2218-273X/13/4/604Heat Shock ProteinsHSP70leukemialymphomamyelomatherapeutics |
| spellingShingle | Nayla Mouawad Guido Capasso Edoardo Ruggeri Leonardo Martinello Filippo Severin Andrea Visentin Monica Facco Livio Trentin Federica Frezzato Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases? Biomolecules Heat Shock Proteins HSP70 leukemia lymphoma myeloma therapeutics |
| title | Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases? |
| title_full | Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases? |
| title_fullStr | Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases? |
| title_full_unstemmed | Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases? |
| title_short | Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases? |
| title_sort | is it still possible to think about hsp70 as a therapeutic target in onco hematological diseases |
| topic | Heat Shock Proteins HSP70 leukemia lymphoma myeloma therapeutics |
| url | https://www.mdpi.com/2218-273X/13/4/604 |
| work_keys_str_mv | AT naylamouawad isitstillpossibletothinkabouthsp70asatherapeutictargetinoncohematologicaldiseases AT guidocapasso isitstillpossibletothinkabouthsp70asatherapeutictargetinoncohematologicaldiseases AT edoardoruggeri isitstillpossibletothinkabouthsp70asatherapeutictargetinoncohematologicaldiseases AT leonardomartinello isitstillpossibletothinkabouthsp70asatherapeutictargetinoncohematologicaldiseases AT filipposeverin isitstillpossibletothinkabouthsp70asatherapeutictargetinoncohematologicaldiseases AT andreavisentin isitstillpossibletothinkabouthsp70asatherapeutictargetinoncohematologicaldiseases AT monicafacco isitstillpossibletothinkabouthsp70asatherapeutictargetinoncohematologicaldiseases AT liviotrentin isitstillpossibletothinkabouthsp70asatherapeutictargetinoncohematologicaldiseases AT federicafrezzato isitstillpossibletothinkabouthsp70asatherapeutictargetinoncohematologicaldiseases |